Board of Directors

Bruce Eaton

Dr. Eaton serves as Chairman and Chief Executive Officer of i2 Pharmaceuticals.  He has been active in commercial Bioscience endeavors in Colorado and California and held several executive-level leadership positions.   With 35 years in both therapeutics and human diagnostics he is passionate about human health and wellness.  His biotech experience also includes participation in successful transitions of private companies becoming public. Dr. Eaton has to date founded five companies in the U.S. focused on pharmaceuticals or diagnostics. Dr. Eaton has notable experience in M&A and post-acquisition integration.  He has been involved in the development of FDA approved diagnostic and therapeutic products, as well as, establishing profitable service businesses for the translational medicine life sciences market. Early in his biotech career he served as Vice President of Chemistry at NeXstar Pharmaceuticals where he directed the efforts of more than 50 scientists including the group responsible for the production of the first successful aptamer IND, NX1838 now known as Macugen™ (Eyetech Pharmaceuticals), marketed by Pfizer for age-related macular degeneration.  Leading this chemistry effort, he was responsible for the acquisition and operation of chemistry companies in both the US and Europe. Dr. Bruce Eaton is an accomplished innovator with more than 80 patents issued worldwide. Dr. Eaton received his Ph.D. degree in Chemistry from the University of California at Berkeley.  In addition to his role as Chairman and CEO of i2 Pharmaceuticals, he currently serves on the board of directors of Velocity Sciences, Galaxy Ophthalmics, Lumos Technology, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) and the Colorado Bioscience Association (CBSA).

Rajen Dalal

Rajen Dalal is CEO of Proxim Diagnostics. Previously, he was a Managing Director at Synergenics LLC and CEO of ReLIA Diagnostic Systems, Inc., making blood tests used in emergency medicine (assets were acquired by Yunfeng Capital). He was CEO of Guava Technologies (acquired by Millipore), President of Chiron’s Blood Testing division, HIV, HCV, HBV, West Nile and other transfusion transmitted agents (acquired by Novartis/Grifols). At Chiron, he was also VP Corporate Development and earlier worked with McKinsey & Co in New York. He is a graduate of the University of Chicago, MIT and St. Xavier’s College, Bombay, with degrees in business, biochemical engineering and chemistry respectively.  He has served on the board of several life science companies and is emeritus board member of Outward Bound California, a youth oriented community service organization.

Michael Horowitz

Michael Horowitz has worked in the biotech industry for over a decade. In that time, he has served in various operational and legal roles. Most recently, Michael served as the Chief Operating Officer and General Counsel of Sea Lane Biotechnologies, LLC overseeing all aspects of the company, including operations, research, finance, legal and human resources as well as negotiating multi-year, multi-target licensing deals. Michael has been a co-author on numerous scientific publications and co-inventor on several patents. Prior to Sea Lane, Michael was an attorney at Wilson, Sonsini, Goodrich and Rosati law firm where he specialized in corporate law including securities law, mergers and acquisitions, initial public offerings and private company financings and management. Michael’s primary focus was on high tech and biotech start-ups. Michael obtained his Juris Doctorate at Duke University School of Law in Durham, North Carolina. He serves on the board of multiple organizations and institutions including Lucky Dog Animal Rescue and the Riekes Center for Human Enhancement.